P1.15-15 Real-World Experience With Afatinib After Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.947
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy